The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
General Description Immunotherapy is being explored in many tumor types with encouraging results, but there is limited investigation of this modality for patients with NET. In this project, we will…
…treatments for neuroendocrine tumors (NETs), an uncommon and poorly understood cancer, which occurs in the body’s hormone-producing cells. Immunotherapy Update: What We’ve Learned Immunotherapy has been called one of the…
…15;17(4):888-95. doi: 10.1158/1078-0432.CCR-10-1706. Epub 2011 Feb 8. Citations 1: Kaufman HL, Bommareddy PK. Two roads for oncolytic immunotherapy development. J Immunother Cancer. 2019 Feb 1;7(1):26. doi: 10.1186/s40425-019-0515-2. PubMed PMID: 30709365;…
…grants. We hope the discoveries from these projects will lead to improved treatment options for patients.” NETRF is supporting a new pioneering approach to NET immunotherapy with a Petersen Accelerator…
…three days, sessions were devoted to the biological origins of neuroendocrine neoplasms, (NENs), immunotherapy, radionuclide therapy (PRRT), and drug development. Scientists spoke about what we know and don’t know about…
…a groundbreaking neoantigen-based (abnormal proteins specific to cancer cells) vaccination strategy, offering new hope for patients with aggressive PanNENs when traditional immunotherapy is not feasible. Why is this important? Understanding…
…neuroendocrine tumors are resistant to conventional immunotherapy with checkpoint inhibitors. Other agents are necessary to activate tumor infiltrating lymphocytes (TILs). Our goal is to develop a BiTE-like molecule that targets…
…University 11:45-12:00PM – Therapies targeting CDK4/6 cause regression, immune cell activation, and sensitization to PD-L1 immunotherapy in pancreatic neuroendocrine tumors Dawn Quelle, PhD, University of Iowa 12:00-12:15PM – A novel…
…cancer (oncology), blood (hematology), radiology, pathology, gastroenterology, endocrinology, and nutrition. Mount Sinai is working to find the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches…
…Fernandez-Cuesta and colleagues showed supra-carcinoids had a high expression of immune checkpoint genes. These experiments will further explore the potential of immunotherapy. What is the next step? The laboratory models…
